For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Zymeworks' collaborator BeOne Medicines secured the approval under the terms of their Asia-Pacific licence and partnership ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Fig 1. CONSORT diagram (patient disposition). HER3, human epidermal growth factor receptor 3; PD, progressive disease. Fig 2. Kaplan-Meier plots of (A) PFS and (B) DOR, both by BICR per RECIST 1.1.

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

Increased consumption of olive oil may reduce the risk for specific subtypes of breast cancer, according to results of a prospective study.

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...

Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer: Basel Tuesday, June 3, 2025, 18:00 Hrs [IST] Novarti ...

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 ...